Abstract: A method is disclosed of treating pain with senicapoc, a potent Ca2+-activated K+ channel, KCa3.1 antagonist in CNS-resident microglia. Senicapoc is shown to cause in a decrease of IL-1? and NO release from microglia cells vivo and in vitro. Because of contribution of KCa3.1 to neuropathological processes, senicapoc is useful in the treatment of chronic, neuropathic, visceral, and inflammatory pain and the reversal of tactile allodynia.
Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing cardiovascular-related diseases in subject in need thereof.
Type:
Grant
Filed:
January 13, 2021
Date of Patent:
September 13, 2022
Assignee:
Amarin Pharmaceuticals Ireland Limited
Inventors:
Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
Abstract: Compositions and methods of treating anxiety or stress in an animal are disclosed. Compositions and methods of reducing or preventing elevated levels of 4-EPS are disclosed. Compositions and methods for promoting growth of beneficial microbes in an animal's microbiome and inhibiting growth of non-beneficial microbes are disclosed. The methods comprise administering to the animal an effective amount of n-3 fatty acids, antioxidants, insoluble fiber and soluble fiber in an effective ratio of insoluble fiber and soluble fiber. Compositions comprise effective amounts of n-3 fatty acids, antioxidants, insoluble fiber and soluble fiber in an effective ratio of insoluble fiber and soluble fiber.
Abstract: The present disclosure relates to a pharmaceutical composition for suppressing cancer metastasis containing, as an active ingredient, an activator compound of the cancer metastasis inhibitor Nm23, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof. The compound according to the present disclosure may suppress the metastasis of cancer cells by promoting the activity of Nm23 associated with cancer metastasis, and thus may be useful as a pharmaceutical composition for suppressing cancer metastasis.
Type:
Grant
Filed:
April 30, 2018
Date of Patent:
July 19, 2022
Assignee:
EWHA UNIVERSITY—INDUSTRY COLLABORATION FOUNDATION
Inventors:
Kong Joo Lee, Hee-Yoon Lee, Je Jin Lee, Eun-Kyoung Seo, Eun Sun Lee, Hwang Suk Kim, Hongsoo Lee
Abstract: Provided herein are compositions, methods, systems and/or kits for preventing and/or treating neoplasms using at least one of quercetin, sodium phenyl butyrate and epigallocatechin-3-gallate in combination with one or more anti-cancer agents. The compositions, methods, systems and/or kits are used to prevent and/or treat neoplasms that are resistant to the one or more anti-cancer agents when administered alone.
Abstract: A method of preventing or treating a subject suffering from a flavivirus infection by administering an effective amount of berbamine or its analogue to the subject, berbamine has a structure of Formula (I), wherein the flavivirus infection is caused by Japanese encephalitis virus, Zika virus or Dengue virus. A method of inhibiting the entry of a flavivirus, an enterovirus and/or a lentivirus into host cells includes contacting the host cells with an effective amount of berbamine of its analogue, berbamine has a structure of Formula (I), wherein the flavivirus is Japanese encephalitis virus, Zika virus or Dengue virus.
Type:
Grant
Filed:
September 4, 2019
Date of Patent:
June 14, 2022
Assignees:
City University of Hong Kong, 6J Biotechnology (Hong Kong) Limited
Abstract: An antimicrobial composition containing a synergistic combination of an imidazole antifungal agent and activated creatinine is provided, wherein the imidazole antifungal agent represents in the range of about 0.5 mol % to about 30 mol % of the combination of the antifungal agent and the activated creatinine in the composition. Methods for treating bacterial infections, fungal infections, viral infections, and wounds are also provided, as are other methods of use, including methods for disinfecting inert surfaces, methods for preserving food products, and methods for treating plants. In addition, the invention provides a method for enhancing the antifungal effect of an imidazole antifungal agent as well as a method for enhancing the antibacterial effect of activated creatinine. Compositions and methods involving use of activated 2-amino-imidazol-4-one analogs other than activated creatinine are also provided.
Type:
Grant
Filed:
December 27, 2017
Date of Patent:
June 7, 2022
Assignee:
Board of Regents of the University of Nebraska
Abstract: Blood and platelet storage and rejuvenating compositions that include triciribine, triciribine metabolites, triciribine analogs, and mixtures of the same are disclosed. Such compositions can be useful in methods for treating (e.g., storing and rejuvenating) red blood cells and platelets.
Abstract: The present invention provides a composition for inhibiting proliferation of a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative, which contains a fatty acid having 18 carbon atoms and a hydroxyl group at the 10-position as an active ingredient. Furthermore, the present invention provides a composition for preventing or treating a disease caused by a bacterium provided with a menaquinone synthesis route via futalosine or a futalosine derivative.
Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
Type:
Grant
Filed:
June 15, 2020
Date of Patent:
May 24, 2022
Assignee:
Amazentis SA
Inventors:
Penelope Andreux, Christopher Rinsch, William Blanco-Bose
Abstract: The present invention relates to a composition of less than or equal to about 1% of pheromones useful to treat or prevent a behavioral stress problem of a non-human mammal. It also relates to a device comprising said composition and to a method for preventing and/or treating stress-related behaviors in a non-human mammal, by using said composition or device.
Abstract: A method of treating a triterpene-responsive condition, disease or disorder in a subject by administration of an improved triterpene-based composition is provided. An improved triterpene-based composition comprising at least two or at least three triterpenes present at a molar ratio as described herein is also provided.
Type:
Grant
Filed:
March 8, 2021
Date of Patent:
May 17, 2022
Assignee:
PHOENIX BIOTECHNOLOGY, INC.
Inventors:
Robert A. Newman, Otis C. Addington, Donald C. Lo, Linda S. Kaltenbach, Peiying Yang
Abstract: Provided herein are small molecule inhibitors of NSD1, NSD2 and/or NSD3 activity, and methods of use thereof for the treatment of disease, including leukemia, breast cancer, osteosarcoma, lung and prostate cancers and other solid tumors as well as other diseases dependent on the activity of NSD1, NSD2 and/or NSD3.
Type:
Grant
Filed:
December 7, 2018
Date of Patent:
May 10, 2022
Inventors:
Tomasz Cierpicki, Jolanta Grembecka, Huang Huang, Sergei Zari, Hyo Je Cho, Mykhaylo Potopnyk, Sergii Dudkin, Wenbing Chen, Yassir Adam, Christina Howard, EunGi Kim
Abstract: The present disclosure relates to birch bark extracts, methods of producing such extracts, stable pharmaceutical compositions containing such extracts and methods of using of such extracts. The birch bark extracts of the present disclosure contain triterpenes, which are known to improve wound healing.
Type:
Grant
Filed:
August 3, 2021
Date of Patent:
March 8, 2022
Assignee:
Amryt Research Limited
Inventors:
John Ashleigh Watson, Sebastian Jäger, Tobias Zahn
Abstract: Human therapeutic treatment compositions comprise at least two of a curcumin component, a harmine component, and an isovanillin component, and preferably all three in combination. The agents are effective for the treatment of human conditions, especially human cancers.
Abstract: The present invention provides a composition comprising a mixture of an exogenous ketone body, an exogenous NAD modulator and a methyl donor. Typically, exogenous NAD modulator is an exogenous nicotinamide adenine dinucleotide (NAD) precursor. The present invention also provides a method of using such a composition for treating various clinical conditions, including metabolic disorders and neurocognitive impairments. The compositions of the invention can also be used to improve human performance in various competitive or environmental conditions.